Perrigo traded at $14.21 this Friday January 30th, increasing $0.47 or 3.42 percent since the previous trading session. Looking back, over the last four weeks, Perrigo gained 2.16 percent. Over the last 12 months, its price fell by 42.61 percent. Looking ahead, we forecast Perrigo to be priced at 13.58 by the end of this quarter and at 12.40 in one year, according to Trading Economics global macro models projections and analysts expectations.
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S), Mexico and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod and Firefly. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies and e-commerce channels.